Nivolumab Treatment Beyond Investigator-Assessed Progression: Extended Follow-up in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 CheckMate 205 Study

被引：7

作者：

Cohen, Jonathon B. ^{[1
]}

Kuruvilla, John ^{[2
,3
]}

Engert, Andreas ^{[4
]}

Ansell, Stephen M. ^{[5
]}

Younes, Anas ^{[6
]}

Lee, Hun Ju ^{[7
]}

Trneny, Marek ^{[8
,9
]}

Savage, Kerry J. ^{[10
]}

Ramchandren, Radhakrishnan ^{[11
]}

Collins, Graham P. ^{[12
]}

Zinzani, Pier Luigi ^{[13
]}

De Boer, Jan Paul ^{[14
]}

Shipp, Margaret A. ^{[15
]}

Santoro, Armando ^{[16
]}

Timmerman, John M. ^{[17
]}

Sacchi, Mariana ^{[18
]}

Sy, Oumar ^{[18
]}

Armand, Philippe ^{[19
]}

机构：

[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[2] Univ Toronto, Toronto, ON, Canada

[3] Princess Margaret Canc Ctr, Toronto, ON, Canada

[4] Univ Hosp Cologne, Cologne, Germany

[5] Mayo Clin, Rochester, MN USA

[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[8] Charles Univ Prague, Prague, Czech Republic

[9] Gen Univ Hosp Prague, Prague, Czech Republic

[10] British Columbia Canc, Vancouver, BC, Canada

[11] Barbara Ann Karmanos Canc Inst, Detroit, MI USA

[12] Churchill Hosp, Oxford Canc & Haematol Ctr, Oxford, England

[13] Univ Bologna, Inst Hematol L e A Seragnoli, Bologna, Italy

[14] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands

[15] Dana Farber Canc Inst, Ctr Hematol Oncol, Boston, MA 02115 USA

[16] Humanitas Univ, Humanitas Canc Ctr, Rozzano Milan, Italy

[17] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA

[18] Bristol Myers Squibb, Princeton, NJ USA

[19] Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-114502

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2932

引用

页数：4

共 50 条

[31] Results From a Phase 1/2 Study of Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (02) : 12 - 13
[32] Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma
Herrera, Alex F.
Moskowitz, Alison J.
Bartlett, Nancy L.
Vose, Julie M.
Ramchandren, Radhakrishnan
Feldman, Tatyana A.
LaCasce, Ann S.
Ansell, Stephen M.
Moskowitz, Craig H.
Fenton, Keenan
Ogden, Carol Anne
Taft, David
Zhang, Qu
Kato, Kazunobu
Campbell, Mary
Advani, Ranjana H.
BLOOD, 2017, 130
[33] Sintilimab for relapsed/refractory classical Hodgkin's lymphoma: Extended follow-up on the multicenter, single-arm phase II ORIENT-1 study.
Su, Hang
Song, Yongping
Jiang, Wenqi
Sun, Xiuhua
Qian, Wenbin
Zhang, Wei
Gao, Yuhuan
Jin, Zhengming
Zhou, Jianfeng
Jin, Chuan
Zou, Liqun
Qiu, Lugui
Li, Wei
Yang, Jianmin
Hou, Ming
Zeng, Shan
Liu, Peng
Shi, Yuankai
Zhou, Hui
Wang, Shuyan
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[34] Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study
Moskowitz, Alison J.
Advani, Ranjana H.
Bartlett, Nancy L.
Vose, Julie M.
Ramchandren, Radhakrishnan
Feldman, Tatyana A.
LaCasce, Ann S.
Christian, Beth A.
Ansell, Stephen M.
Moskowitz, Craig H.
Brown, Lisa
Taft, David
Ansari, Sahar
Zak, Daniel E.
Sacchi, Mariana
Manley, Thomas
Herrera, Alex F.
BLOOD, 2019, 134
[35] Nivolumab and brentuximab vedotin (BV)-based, response-adapted treatment in primary refractory patients (pts) and in pediatric pts with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) in the phase 2 CheckMate 744 study
Mauz-Koerholz, C.
Leblanc, T.
Harker-Murray, P.
Mascarin, M.
Michel, G.
Cooper, S.
Beishuizen, A.
Leger, K. J.
Garaventa, A.
Buffardi, S.
Brugieres, L.
Kelly, K. M.
Cole, P. D.
Drachtman, R. A.
Manley, T.
Francis, S.
Sacchi, M.
Daw, S.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 161 - 162
[36] Nivolumab plus Doxorubicin, Vinblastine and Dacarbazine for newly diagnosed advanced-stage classical Hodgkin lymphoma: CheckMate 205 Cohort D 2-year follow-up results
Engert, A.
Domingo-Domenech, E.
Ramchandren, R.
Rueda, A.
Trneny, M.
Feldman, T.
Lee, H. J.
Provencio, M.
Sillaber, C.
Cohen, J. B.
Savage, K. J.
Willenbacher, W.
Sumbul, A.
Sacchi, M.
Armand, P.
Ansell, S. M.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 162 - 162
[37] Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma
Herrera, Alex F.
Bartlett, Nancy L.
Ramchandren, Radhakrishnan
Vose, Julie M.
Moskowitz, Alison J.
Feldman, Tatyana A.
LaCasce, Ann S.
Ansell, Stephen M.
Moskowitz, Craig H.
Fenton, Keenan
Kato, Kazunobu
Fong, Abraham
Advani, Ranjana H.
BLOOD, 2016, 128 (22)
[38] Checkmate 205: Nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) A phase 2 study.
Younes, Anas
Santoro, Armando
Zinzani, Pier Luigi
Timmerman, John
Ansell, Stephen Maxted
Armand, Philippe
Fanale, Michelle A.
Ratanatharathorn, Voravit
Kuruvilla, John
Cohen, Jonathon Brett
Collins, Graham P.
Savage, Kerry J.
Trneny, Marek
Kato, Kazunobu
Farsaci, Benedetto
Parker, Susan M.
Rodig, Scott J.
Shipp, Margaret Ann
Engert, Andreas
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[39] NIVOLUMAB RE-TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA: SAFETY AND EFFICACY OUTCOMES FROM A PHASE 1 CLINICAL TRIAL
Ansell, S.
Armand, P.
Timmerman, J.
Shipp, M.
Mckiver, M. Popa
Zhu, L.
Lesokhin, A. M.
HAEMATOLOGICA, 2016, 101 : 49 - 49
[40] Tislelizumab (BGB-A317) for relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL): Long-term follow-up efficacy and safety results from a phase 2 study.
Song, Yuqin
Gao, Quanli
Zhang, Huilai
Fan, Lei
Zhou, Jianfeng
Zou, Dehui
Li, Wei
Yang, Haiyan
Liu, Ting
Wang, Quanshun
Lv, Fangfang
Guo, Haiyi
Yang, Liudi
Huang, Jane
Novotny, William F.
Wang, Yidi
Zhu, Jun
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →